<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="220">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209949</url>
  </required_header>
  <id_info>
    <org_study_id>US10179</org_study_id>
    <nct_id>NCT01209949</nct_id>
  </id_info>
  <brief_title>Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris</brief_title>
  <official_title>Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to
      treat mild to moderate acne vulgaris using efficacy measurements, quality of life
      instruments, and video diaries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants who were a Success (Subject's Global Assessment of 'Clear or 'Almost Clear') at week 12. Subject's Global Assessment is measured on a scale (Clear, Almost Clear, Mild, Moderate, Severe, Very Severe) with Clear being best and Very Severe being worst.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in lesions counts (inflammatory, non-inflammatory, and total) at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tolerability Assessments Resulting in an Adverse Event</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with tolerability assessments resulting in an adverse event. Tolerability assessments include erythema (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Scaling (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Dryness (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Stinging/Burning (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with a score of None being best and a score of Severe being worst.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel</intervention_name>
    <description>Apply adapalene BPO gel once daily in the evening for 12 weeks</description>
    <arm_group_label>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel</arm_group_label>
    <other_name>EpiduoÂ® Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, aged 16 to 25 years inclusive;

          -  Subjects with mild or moderate facial acne (Investigator's Global Assessment (IGA) =
             2 or 3;

          -  A minimum of 10 inflammatory lesions (papules and pustules) on the face (excluding
             the nose);

          -  Subjects who agree to be photographed at each visit;

          -  Subjects who agree to be video recorded by study designated staff members. They
             should be able to clearly and comfortably communicate their responses to questions
             and express their thoughts related to their disease and treatment throughout the
             study

        Exclusion Criteria:

          -  Subjects with nodules, cysts, acne conglobata, acne fulminans, secondary acne
             (chloracne, drug-induced acne, etc.) or severe acne requiring systemic treatment;

          -  Subjects with a wash-out period for topical acne treatment on the face less than 30
             days

          -  Subjects with a wash-out period for systemic acne treatment less than 30 days with
             the exception of isotretinoin which requires a washout of 4 months;

          -  Subjects who are currently being treated with antibiotics;

          -  Subjects who foresee intensive ultraviolet (UV) exposure during the study (mountain
             sports, UV radiation, sunbathing, tanning beds, etc.);

          -  Subjects who refuse photographic and videography procedures and/or refuse to sign a
             full release for their use in promotional materials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald W Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, L.P.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas J. Stephens and Associates</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>January 18, 2012</lastchanged_date>
  <firstreceived_date>September 24, 2010</firstreceived_date>
  <firstreceived_results_date>December 13, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
